Biospecimen Procurement Market Overview
The biospecimen procurement market is estimated to be worth $52 million in 2021 and is expected to grow at CAGR of 16% during the forecast period.
Biomedical research is an evolutionary process involving a wide array of research experiments focused on studying diseases and their treatment options; biospecimens are credited as critical components of this process, starting from drug development to clinical trials and epidemiological investigations. Further, in the field of precision medicine, biospecimens act as a link between the biology of a patient and the development of customized therapy. However, procurement and storage of a high quality biospecimen and its analytical evaluation has remained a challenge in the pharmaceutical industry, resulting in delays in research and drug approval timeline. Reliable and efficient traceability of biospecimens demands unique identifiers, advanced data management and quality control systems. Moreover, there are legal and ethical concerns associated with biobanking, and laws and regulations regarding the upkeep of human biospecimens are still evolving.
Over the last few decades, the field of biospecimen research has witnessed significant technological advancements resulting in the procurement of high quality biospecimens for molecular research purposes. In fact, new best practices and improved methods of procurement, processing and storage of biospecimens have also been introduced to the industry. The pharmaceutical industry has seen a significant shift towards outsourcing the bioanalytical services to leverage cost-effective methods and overcome the existing capacity constraints. This shift is evident from the increase in partnership activity focused on expanding the existing capabilities of service providers and offering biospecimen procurement and analytical services. Based on the prevalent trends, we believe that more developers and innovators are likely to rely on the contract research organizations in order to deal with the existing challenges and drive innovation in drug development, thereby, increasing the opportunities for these service providers in the foreseen future.
Key Biospecimen CRO in Biospecimen Procurement Market
Examples of key biospecimen procurement CRO (which have also been profiled in this market report; the complete list of companies is available in the full report) include BioChain Institute, BioIVT, Creative Bioarray, Discovery Life Sciences, Infinity BiologiX, Precision for Medicine, PrecisionMed, Medicove, National BioService and REPROCELL. This biospecimen procurement market report includes an easily searchable excel database of all the companies providing biospecimens for biomedical research, worldwide.
Recent Developments in Biospecimen Procurement Market:
Several recent developments have taken place in the field of biospecimen procurement market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
- In April 2026, Panome Bio entered into a collaboration with Audubon Bioscience in order to deliver end-to-end FFPE biospecimen and metabolic profiling solutions, creating a seamless path from ethical tissue acquisition through deep metabolic discovery for researchers in the biospecimen procurement ecosystem.
- In March 2026, iSpecimen achieved a rapid procurement milestone by successfully delivering high-quality influenza biospecimens to life science researchers through its global marketplace platform connecting suppliers and demand for biospecimen procurement needs.
- In March 2026, REPROCELL expanded its Bioserve Partner Network to broaden the spectrum of specimen types available, reducing complications in biospecimen procurement and delivering quality human biospecimens suitable for commercial research at industrial scale.
- In January 2026, ABS Bio announced the acquistion of Cureline to broaden access to high-quality specimens, strengthen its position in specimen procurement, cell culture, and histology services across global research networks.
- In December 2025, iSpecimen priced a $5.5 million private placement with accredited investors via Series C Convertible Preferred Stock, securing gross proceeds for marketing, working capital, and general corporate purposes to support its biospecimen marketplace platform.
Scope of the Report
The “Biospecimen Procurement Market by Therapeutic Area (Oncological Disorders and Other Disorders), Type of Biospecimen for Oncological Studies (FFPE Tissue, Frozen Tissue, Plasma / Serum and Other Biospecimens), Type of Biospecimen for Non-Oncological Studies (Blood Products, Human Tissue and Other Biospecimens), Key Geographical Regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain and Other European Countries) and Asia Pacific (China, India, Japan and other Asia-Countries and Rest of the World)): Industry Trends and Global Forecasts, 2021-2030” market report features an extensive study on the current market landscape, market size, market growth, market share, market forecast, market outlook and future opportunities for the biospecimen procurement market. The market research report underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in biospecimen procurement market. Amongst other elements, the market research report includes:
- A detailed review of the overall landscape of the companies that claim to offer research services related to biospecimens, including analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of blood products offered (plasma, serum, whole blood, blood cells and bone marrow), types of human tissues offered (Formalin-Fixed Paraffin-Embedded, frozen tissue and fresh tissue), types of biofluids offered (urine, saliva, cerebrospinal fluid, swab, synovial fluid, others), types of other biospecimens offered (fecal matter and nucleic acid), types of analytical services offered (histological analysis, target validation, tissue microarray, tumor tissue analysis and cell based assay), types of samples offered (healthy and diseased samples), types of accreditations received, and geographical reach (North America, Europe, Asia-Pacific and Rest of the World).
- A detailed competitiveness analysis of the biospecimen contract research service providers based in different geographies offering services from their own biorepository or through the network of biorepositories, based on portfolio strength (in terms of number of biospecimens, number of analytical services and number of samples offered), service strength (in terms of number of accreditations and geographical reach), supplier strength (in terms of years of experience in this field and company size).
- Tabulated profiles of key players offering a wide range of research services for the biospecimens across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, details on its biospecimen related services offered, types of blood products offered, types of human tissues offered, types of other biospecimens offered, types of analytical services offered, types of samples offered, geographic availability of the services, recent developments and an informed future outlook.
- An analysis of partnerships established in biospecimen procurement market since 2015, covering the deals focused on the services related to biospecimens, merger / acqusition, service agreement, service alliance, distribution agreement, joint venture and other agreements.
- A case study of the overall landscape of biospecimen procurement service providers (commercial biobanks), based on a number of parameters, such as year of establishment, company size, location of headquarters, types of services offered (sample biocollections, sample processing, sample logistic / transportation and sample storage), types of biospecimens handled (biofluids, human cells and tissues), therapeutic area (cardiovascular disorders, oncological disorders, neurological disorders, infectious diseases and other therapeutic areas). In addition, it presents a competitiveness analysis of the commercial biobanks based on the availability of their respective biorepositories.
- An in-depth analysis of biospecimen contract research service providers, featuring four schematic representations, namely [A] a grid analysis based on the year of establishment and type of analytical services offered, [B] a representation based on the therapeutic area and most active players, [C] an analysis based on the company size and therapeutic area, and [D] a world map representation highlighting the regional distribution of biospecimen research service providers, based on the locations of their biorepositories.
The key objective of biospecimen procurement market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for biospecimen procurement market during the forecast period. Based on different parameters, such as overall human biological sample market, share of commercial biobanks and share of biospecimen contract research service providers, we have provided informed estimates on the evolution of the market for the forecast period 2021-2030. In order to provide a detailed future outlook, year-wise projections of the current and forecasted opportunity have been further segmented across [A] Therapeutic Area (Oncological Disorders and Other Disorders), [B] Type of Biospecimen for Oncological Studies (FFPE, Frozen Tissue, Plasma / Serum and Other Biospecimens), [C] Type of Biospecimen for Non-Oncological Studies (Blood Product, Human Tissue and Other Biospecimens), [D] Key Geographical Regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain and Other European Countries) and Asia Pacific (China, India, Japan and other Asia-Countries and Rest of the World). In order to account for the uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the market report are backed by a deep understanding of key insights generated from both secondary and primary research. The information presented in this market research report was also influenced by discussions held with senior stakeholders in this industry. The market research report features detailed transcripts of interviews held with the following individuals:
- Ramchandra Rao (Managing Director and Business Development Head, BioSpecimen Solutions)
- Oleg Granstrem (Director of Business Development, National BioService)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Frequently Asked Questions
Question 1: What is a biospecimen?
Answer: A biospecimen is a biological sample obtained from people, including tissue samples, plasma, blood and urine. Biospecimen is primarily used for research and diagnosis purposes.
Question 2: How big is the biospecimen procurement market?
Answer: The biospecimen procurement market size is estimated to be worth $52 million in 2021.
Question 3: What is the projected market growth of the biospecimen procurement market?
Answer: The biospecimen procurement market is expected to grow at compounded annual growth rate (CAGR) of 16% during the forecast period 2021 – 2030.
Question 4: Who are the leading biospecimen CRO in the biospecimen procurement market?
Answer: Examples of key companies engaged in supplying biospecimens for biomedical research market (which have also been profiled in this market report; the complete list of companies is available in the full report) include BioChain Institute, BioIVT, Creative Bioarray, Discovery Life Sciences, Infinity BiologiX, Precision for Medicine, PrecisionMed, Medicove, National BioService and REPROCELL.
Question 5: How many companies are currently engaged in the biospecimen procurement market?
Answer: Presently, more than 40 biospecimen CRO are working in the biospecimen procurement industry.
Question 6: How many partnership deals have been inked between players engaged in the biospecimen procurement market?
Answer: Over 70 partnership deals have been inked between biospecimen CRO engaged in the biospecimen procurement market, indicating the consolidation effort of the stakeholders.
